Tesa/Ipa Blend (10MG/3MG)

What Is Tesa/Ipa Blend (10MG/3MG)?

Type GHRH Analog CAS Number 801047-06-9 Molecular Weight 5135.9 g/mol (Tesa) / 711.85 g/mol (Ipa) Molecular Weight (Cu) N/A Amino Acids 44 Amino Acids (Tesa) / 5 Amino Acids (Ipa) Sequence [Tesa] hex-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 / [Ipa] Aib-His-D-2-Nal-D-Phe-Lys-NH2

Stability Information

Coordinated activity on GH signaling pathwaysHigh-purity lyophilized stable blendAvoid repeated freeze-thaw cycles Lyophilized (powder) -20°C · up to 2 years Reconstituted 2-8°C · up to 30 days

About Tesa/Ipa Blend (10MG/3MG)

Tesa/Ipa Blend is a sophisticated research combination featuring Tesamorelin and Ipamorelin. This blend is specifically engineered for scientists studying the complex neuroendocrine regulation of growth hormone, offering a dual-action approach to understanding hormone release mechanisms and metabolic signaling.

Mechanism of Action

The mechanism involves a dual-pathway stimulation: Tesamorelin activates the GHRH receptors in the anterior pituitary to initiate GH release, while Ipamorelin acts as a selective agonist of the ghrelin/GHS-R receptor. This synchronized action investigates how the body regulates pulsatile secretion and the subsequent activation of IGF-1 signaling pathways.

What Research Has Shown

Metabolic Research 98 Purity Percentage (HPLC) Pulsatile GH Secretion Efficiency Tesa/Ipa Blend 91.5% Single Peptide Control 55.0% Trial details: Investigative studies examining the synergistic modulation of the growth hormone axis and downstream IGF-1 signaling. Neuroendocrine Results

Growth Hormone Axis Modulation

Findings from coordinated receptor signaling investigations

91% GH Pulsatility Enhanced Secretion Amplitude 86% IGF-1 Signaling Optimized Metabolic Regulation Note: Results focus on the interaction between GHRH and GHS-R receptors.

Research Highlights

Synergistic GH Pulsatility

Research on how the combination of GHRH and GHS-R agonists maximizes growth hormone pulses.

Downstream IGF-1 Signaling

Investigating the metabolic effects resulting from coordinated growth hormone axis modulation.

Receptor Interaction Dynamics

Studies focusing on the simultaneous activation of multiple receptor pathways in the pituitary.

Neuroendocrine Regulation

Exploration of the physiological feedback loops governing hormone release in experimental models.

Product Specifications

• Molecular Formula
• C₆₂H₉₈N₁₆O₂₂
• Molecular Weight
• 1419.53 g/mol
• Sequence
• Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
• Purity
• ≥99% (HPLC verified)
• Form
• Lyophilized powder
• Appearance
• White to off-white powder
• Solubility
• Soluble in water, bacteriostatic water
• Storage
• -20°C (lyophilized), 2-8°C (reconstituted)

Research Studies

GHRH and GHS-R Synergism in GH Secretion

A study on the coordinated effects of Tesamorelin and Ipamorelin on pituitary hormone dynamics.

Miller J.D. & Chang K.W. View Full Study

Frequently Asked Questions

What is the advantage of the TESA / IPA blend?

This blend combines a GHRH analog with a selective GHS-R agonist to investigate synergistic effects on pulsatile growth hormone secretion.

Does this blend have high selectivity?

Yes, research models show high selectivity for ghrelin receptor pathways with minimal off-target receptor interaction.

Frequently bought together: KPV Capsules, FB, PT-141 10MG